Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | S100A9 | P06702 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.32 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870212 | 0.86 | EGFR (0.38) | EGFRERBB2ERBB3ERBB4RHEB | |
| SCHEMBL2053177 | 0.81 | PDE2A (0.36) | EGFRERBB2ERBB3ERBB4BRD4 | |
| SCHEMBL1013714 | 0.77 | NR3C1 (0.40) | AHRRHEBBRD4KDM4E | |
| SCHEMBL6871152 | 0.74 | TRPA1 (0.38) | EGFRERBB2ERBB3ERBB4BRD4 | |
| SCHEMBL2599781 | 0.72 | AHR (0.48) | AHRRHEB | |
| SCHEMBL27934980 | 0.72 | P2RX7 (0.32) | TNNI3K | |
| SCHEMBL7207553 | 0.71 | GPR84 (0.41) | AHRRHEB | |
| SCHEMBL8527274 | 0.70 | KMT2A (0.41) | SMN1; SMN2 | |
| SCHEMBL6437291 | 0.70 | TNF (0.48) | AHRRHEB | |
| SCHEMBL23641363 | 0.69 | TNF (0.44) | EGFRERBB2ERBB3ERBB4AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102470132-B | Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones | SANOFI SA | 2013-11-06 | — | — | CN | disclosed |
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| CN-102470132-A | Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones | SANOFI AVENTIS | 2012-05-23 | — | — | CN | disclosed |
| WO-2011022449-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | CMA1, TPSB2, TPSAB1 | EGFR 2325/4885ERBB2 2282/4885ERBB3 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.